CTRI/2020/06/026001已完成2 期
Randomised Controlled Trial of Ivermectin in hospitalised patients with COVID19 - RIVET-COV
AIIMS New Delhi0 个研究点目标入组 125 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 125
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •diagnosed COVID19 patients admitted to AIIMS COVID facility
- •Age > 18 years
- •Informed consent
- •Non-severe disease: Non-severe disease (Asymptomatic/ Mild
- •disease OR moderate): SpO2>=90% on room
- •air with presence of clinical features of
- •dyspnea and/or hypoxia, fever, cough and/or
- •Respiratory Rate more or equal to 24 per
排除标准
- •Not giving written informed consent
- •ALT/AST >5 times the upper limit of normal.
- •Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR <30).
- •Pregnant or breast feeding.
- •Allergy to any study medication.
- •Severe co-morbidity as per investigatorâ??s assessment
- •Comorbid condition like myocardial infarction or heart failure within 90 days of recruitment.
- •Prolonged QT interval ( >450 ms)
- •Any other concomitant therapeutic trial
- •Weight <15 kg
研究者
相似试验
招募中
3 期
Ivermectin effect in the treatment of patients with covid-19IRCT20190602043787N3Mashhad University of Medical Sciences40
进行中（未招募）
1 期
Study of the efficacy of ivermectin in the treatment and prevention of COVID-19EUCTR2020-001994-66-ESFundació Assistencial Mútua Terrassa266
招募中
不适用
Efficacy of Ivermectin in the treatment of COVID-19IRCT20210901052358N4Shahid Beheshti University of Medical Sciences60
招募中
4 期
A trial of community wide treatment to reduce scabies in a village setting in northern IndiaSkin - Dermatological conditionsInfection - Other infectious diseasesScabiesACTRN12619001712190The Nossal Institute for Global Health (University of Melbourne)2,200
Unknown
3 期
Efficacy of Ivermectin in Outpatients With Non-severe COVID-19Covid19Coronavirus InfectionNCT04834115Universidad Nacional de Asunción400